Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD70-targeted PET/CT in Malignant Cancers
NCT06852638Phase 2Recruiting
- Sponsor
- Renji Hospital
- Start
- Dec 2024
- Primary completion
- Dec 2026
- Modality
- Nanobodies (VHH)
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of [18F]RCCB6, [18F]F-RESCA-R8B4-RenJi Hospital, [68Ga]Ga-NOTA-R8B4, [18F]F-RESCA-RD06 and [68Ga]Ga-NOTA-RD06 in renal cell carcinoma (RCC), lymphoma and nasopharyngeal carcinoma (NPC), sponsored by Renji Hospital. Primary endpoints: Uptake patterns of CD70-targeted tracers at 1 month and Diagnostic value of CD70-targeted immunoPET/CT at 1 month. Started Dec 2024; status: recruiting.
02
Drugs
[18F]RCCB6[18F]F-RESCA-R8B4-RenJi Hospital[68Ga]Ga-NOTA-R8B4[18F]F-RESCA-RD06[68Ga]Ga-NOTA-RD06
03
Conditions
renal cell carcinoma (RCC)lymphomanasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT06852638.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06852638.